04 September 2024
04 September 2024
The combination regimen is approved as a first-line treatment for specific bladder cancers in adults.
The parties will develop RNA polymerases and capping compounds, co-optimised to improve mRNA quality.
Ocaliva’s manufacturer Advanz Pharma said thousands of patients will no longer benefit from the treatment.
RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.
There are currently no approved treatments that can halt or reverse photoreceptor degeneration in patients with retinitis pigmentosa.
The oral solution in the prefilled ENFit syringe offers a safer alternative for adult subarachnoid haemorrhage patients.
IBI363 is undergoing Phase I/II clinical trials in China, the US and Australia.
GLP-1RAs reduce CV risk, including reducing all-cause mortality and risk of MI, promoting weight loss and enhancing blood pressure control.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
